Read by QxMD icon Read

cirrhosis, hepatitis c, HCC

Nearmeen M Rashad, Amal S El-Shal, Sally M Shalaby, Salem Y Mohamed
Hepatitis C virus (HCV) infection remains the main risk factor for chronic hepatitis (CHC), liver cirrhosis, and hepatocellular carcinoma (HCC). Changes in microRNA (miRNA) profiles can be associated with HCV infection and may either favor or inhibit the virus and/or its complication. Moreover, miRNAs have emerged as key regulators of various cancers including HCC. The aim of this work was to investigate the potentail role of miRNA-27a and miRNA-18b expression levels as non-invasive predictive biomarkers of hepatitis C virus-associated HCC...
February 17, 2018: Molecular and Cellular Biochemistry
Patrícia Dos Santos Marcon, Cristiane Valle Tovo, Dimas Alexandre Kliemann, Patrícia Fisch, Angelo Alves de Mattos
AIM: To assess the incidence of hepatocellular carcinoma (HCC) in chronic liver disease due to hepatitis B virus (HBV) or hepatitis C virus (HCV) coinfected with human immunodeficiency virus (HIV). METHODS: A retrospective cohort study was performed, including patients with chronic liver disease due to HBV or HCV, with and without HIV coinfection. Patients were selected in the largest tertiary public hospital complex in southern Brazil between January 2007 and June 2014...
February 7, 2018: World Journal of Gastroenterology: WJG
Marcus M Mücke, Victoria T Mücke, Christian M Lange, Stefan Zeuzem
Direct acting antivirals (DAA) have revolutionized the treatment of hepatitis C virus (HCV). Sustained virological response rates of nearly 100% have become common in the general population. However, physicians face the growing problem of managing HCV in patients with the complications of cirrhosis, eg hepatic decompensation or hepatocellular carcinoma (HCC). Safety and efficacy remain a clinical challenge in these difficult-to-treat patients. This review focuses on the current state of knowledge and treatment regimens in patients with decompensated cirrhosis as well as the potential risk of the development of HCC following DAA therapy...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Bruno Roche, Audrey Coilly, Jean Charles Duclos-Vallee, Didier Samuel
Hepatitis C virus infection is a major cause of chronic hepatitis resulting in cirrhosis and hepatocellular carcinoma (HCC). The recent introduction of direct acting antivirals (DAA), results in sustained virological response (SVR) rates of >90% in treated patients whatever the stage of liver fibrosis with an excellent safety profile. This major advancement has allowed treatment of a larger number of patients, some with more advanced liver dysfunction and a higher risk of HCC. An SVR is associated with a reduced risk of hepatic decompensation, the need for liver transplantation and both liver-related and overall mortality...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Martine Regenboog, Laura van Dussen, Joanne Verheij, Neal J Weinreb, David Santosa, Stephan Vom Dahl, Dieter Häussinger, Meike N Müller, Ali Canbay, Miriam Rigoldi, Alberto Piperno, Tama Dinur, Ari Zimran, Pramod K Mistry, Karima Yousfi Salah, Nadia Belmatoug, David J Kuter, Carla E M Hollak
Gaucher disease (GD) is associated with an increased risk for malignancies. Next to hematological malignancies, the development of solid tumors in several organs has been described. The liver is one of the major storage sites involved in GD pathogenesis, and is also affected by liver-specific complications. In this case series, we describe 16 GD type 1 (GD1) patients from eight different referral centers around the world who developed hepatocellular carcinoma (HCC). Potential factors contributing to the increased HCC risk in GD patients are studied...
February 8, 2018: Journal of Inherited Metabolic Disease
Binhao Zhang, Bixiang Zhang, Zhiwei Zhang, Zhiyong Huang, Yifa Chen, Minshan Chen, Ping Bie, Baogang Peng, Liqun Wu, Zhiming Wang, Bo Li, Jia Fan, Lunxiu Qin, Ping Chen, Jingfeng Liu, Zhe Tang, Jun Niu, Xinmin Yin, Deyu Li, Songqing He, Bin Jiang, Yilei Mao, Weiping Zhou, Xiaoping Chen
Hepatectomy is currently routinely performed in most hospitals in China. China owns the largest population of liver diseases and the biggest number of liver resection cases. A nationwide multicenter retrospective investigation involving 112 hospitals was performed, and focused on liver resection for patients with hepatocellular carcinoma (HCC). 42,573 cases of hepatectomy were enrolled, and 18,275 valid cases of liver resection for HCC patients were selected for statistical analysis. The epidemiology of HCC, distribution of hepatectomy, postoperative complications and prognosis were finally analyzed...
February 2, 2018: Science China. Life Sciences
Yun Zeng, Zhengjie Shen, Wenzhe Gu, Mianhua Wu
This study aimed to explore crucial genes, transcription factors (TFs), and microRNAs (miRNAs) associated with the effects of curcumin against hepatocellular carcinoma (HCC). We downloaded data (GSE59713) from Gene Expression Omnibus to analyze differentially expressed genes (DEGs) between curcumin-treated and untreated HCC cell lines. Then, we identified the disease ontology (DO) and functional enrichment analysis of these DEGs and analyzed their protein-protein interactions (PPIs). Additionally, we constructed TF-target gene and miRNA-target gene regulatory networks and explored the potential functions of these DEGs...
February 2, 2018: Gene
Paolo A Cortesi, Luca S Belli, Rita Facchetti, Chiara Mazzarelli, Giovanni Perricone, Stella De Nicola, Giancarlo Cesana, Christophe Duvoux, Lorenzo G Mantovani, Mario Strazzabosco
Different strategies of DAAs treatment are currently possible both pre and post liver-transplantation (LT). Clinical and economic consequences of these strategies still need to be adequately investigated; this study aims at assessing their cost-effectiveness. A decision-analytical model was created to simulate the progression of HCV-infected patients listed for decompensated cirrhosis (DCC) or for Hepatocellular carcinoma (HCC). Three DAAs treatment strategies were compared: (i) a 12-week course of DAAs prior to transplantation (PRE-LT), (ii) a 4-week course of DAAs starting at the time of transplantation (PERI-LT), and (iii) a 12-week course of DAAs administered at disease recurrence (POST-LT)...
February 6, 2018: Journal of Viral Hepatitis
Yucel Aydin, Animesh Chatterjee, Partha K Chandra, Srinivas Chava, Weina Chen, Anamika Tandon, Asha Dash, Milad Chedid, Martin W Moehlen, Frederic Regenstein, Luis A Balart, Ari Cohen, Hua Lu, Tong Wu, Srikanta Dash
The mechanism why hepatitis C virus (HCV) clearance by direct-acting antivirals (DAAs) does not eliminate the risk of hepatocellular carcinoma (HCC) among patients with advanced cirrhosis is unclear. Many viral and bacterial infections degrade p53 in favor of cell survival to adapt an endoplasmic reticulum (ER)-stress response. In this study, we examined whether HCV clearance by interferon-alpha or DAAs normalizes the ER stress and restores the expression of p53 tumor suppressor in cell culture. We found that HCV infection induces chronic ER stress and unfolded protein response in untransformed primary human hepatocytes...
May 2017: Hepatology Communications
Song-Huy Nguyen-Dinh, Albert Do, Trang Ngoc Doan Pham, Doan Y Dao, Trinh Nhu Nguy, Moon S Chen
AIM: To examine the largest tertiary referral center in southern and central Vietnam from 2010 to 2016, evaluating epidemiological trends of hepatocellular carcinoma (HCC) and viral hepatitis B-C in this resource-limited setting. METHODS: We extracted data of patients receiving care from Cho Ray Hospital (Ho Chi Minh City), the largest oncology referral center in southern and central Vietnam, from 2010 to 2016. We collected information on patient age, gender, geographic distribution, and disease characteristics including disease stage, tumor biomarker levels [serum alpha-fetoprotein (AFP), AFP-L3 isoform percentage, and prothrombin induced by induced by vitamin K absence-II], and serological testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) infections...
January 27, 2018: World Journal of Hepatology
Lei Zhang, Guang-Ye Wu, Yu-Jing Wu, Shu-Ye Liu
The present study aimed to explore the characteristic ions distinguishing different Barcelona stages in patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) using the ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) platform, and to evaluate their value in diagnosing and monitoring the progress of HCC. The serum was sampled from 20 healthy volunteers, 20 patients with HBV-induced cirrhosis and 75 patients with HBV-associated HCC of different BCLC stages. Samples were all examined using UPLC-MS...
January 2018: Oncology Letters
Hirsh D Trivedi, Steven C Lin, Daryl T Y Lau
The emergence of direct-acting antiviral (DAA) therapies and noninvasive measures of liver fibrosis has streamlined the management of patients with chronic hepatitis C virus (HCV) infection. DAA therapy is associated with a significantly higher rate of sustained virologic response (SVR) compared to interferon-based therapies. Concomitantly, validated noninvasive measures of fibrosis allow evaluation of patients for therapy without an invasive liver biopsy. Noninvasive measures of fibrosis can be classified as serologic tests or imaging modalities...
October 2017: Gastroenterology & Hepatology
Luigi Cormio, Vito Mancini, Beppe Calò, Oscar Selvaggio, Teobaldo Mazzilli, Francesca Sanguedolce, Giuseppe Carrieri
RATIONALE: Solitary extramedullary plasmocytoma may arise in any organ, either as a primary tumor or as part of a systemic myeloma; if it rarely affects bladder, it presents with urinary symptoms. We describe the first case of asymptomatic BP occasionally diagnosed in a patient with ascites. PATIENT CONCERNS: A 74-year-old woman with hepatitis C virus (HCV)-related liver cirrhosis presented with ascites and no urinary or other symptoms. DIAGNOSES: Routine blood tests were within normal ranges, except for mild elevation of transaminases due to chronic hepatitis...
December 2017: Medicine (Baltimore)
Xavier Adhoute, Guillaume Penaranda, Jean Luc Raoul, Floriane Sellier, Paul Castellani, Valerie Oules, Herve Perrier, Gaëlle Lefolgoc, Bernard Pol, Manuela Campanile, Olivier Bayle, Patrick Beaurain, Olivier Monnet, Marc Bourlière
BACKGROUND: Direct-acting antivirals (DAAs) therapy against hepatitis C viral (HCV) infection has markedly improved the sustained viral response. However, recent studies have suggested an unsuspected high rate of hepatocellular carcinoma (HCC) recurrence. PATIENTS AND METHODS: A retrospective case-control study was carried out to investigate the impact of DAAs on tumor recurrence in patients with complete response to HCC treatment within our HCV-related cirrhosis cohort...
January 30, 2018: European Journal of Gastroenterology & Hepatology
Hoang Bui Huu, Nhuong Ha Thuc, Hoa Pham Thi Le, Thuy Do Thi Thanh, An Luong Bac, Claudio Tiribelli, Patrizia Pontisso, Andrea Gallotta, Laura Paneghetti, Giorgio Fassina
Viral hepatitis infection is a major global issue and a leading cause of liver disease and associated deaths. Over time, patients infected with hepatitis B (HBV) or C virus (HCV) develop cirrhosis and, eventually, hepatocellular carcinoma (HCC). For this reason, they need to be constantly monitored. Current Asian guidelines recommend the determination of serum alpha-fetoprotein (AFP) together with liver ultrasounds every six months to detect HCC nodules. However, both methods have several limitations, and other biomarkers have been studied for monitoring cirrhosis, including SCCA-IgM, an immune-complex formed by Squamous Cell Carcinoma Antigen and IgM...
January 30, 2018: Scandinavian Journal of Clinical and Laboratory Investigation
Roberta D'Ambrosio, Alessio Aghemo, Maria Grazia Rumi, Elisabetta Degasperi, Angelo Sangiovanni, Marco Maggioni, Mirella Fraquelli, Riccardo Perbellini, William Rosenberg, Pierre Bedossa, Massimo Colombo, Pietro Lampertico
BACKGROUND AND AIM: In patients with HCV-related cirrhosis, a SVR may lead to cirrhosis regression. Whether histological changes translate into prevention of long-term complications, particularly hepatocellular carcinoma (HCC) is still unknown. This was investigated in a cohort of histological cirrhotics who had been prospectively followed-up for 10 years after the achievement of a SVR to IFN. METHODS: 38 SVR cirrhotics who underwent a liver biopsy (LB) 5 years post-SVR were prospectively followed to assess the impact of cirrhosis regression on clinical endpoints...
January 27, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Bui Tien Sy, Nghiem Xuan Hoan, Hoang Van Tong, Christian G Meyer, Nguyen Linh Toan, Le Huu Song, Claus-Thomas Bock, Thirumalaisamy P Velavan
AIM: To investigate possible effects of IRF5 polymorphisms in the 3' UTR region of the IFR5 locus on susceptibility to hepatitis B virus (HBV) infection and progression of liver diseases among clinically classified Vietnamese patients. METHODS: Four IFR5 SNPs (rs13242262A/T, rs77416878C/T, rs10488630A/G, and rs2280714T/C) were genotyped in clinically classified HBV patients [chronic hepatitis B (CHB). n = 99; liver cirrhosis (LC), n = 131; hepatocellular carcinoma (HCC), n = 149] and in 242 healthy controls by direct sequencing and TaqMan real-time PCR assays...
January 14, 2018: World Journal of Gastroenterology: WJG
Marwa Hamdy, Samar Kamal Kassim, Eman Khairy, Mohsen Maher, Khaled Amr Mansour, Ashraf Mohammad Albreedy
Ghrelin (GHRL) has important implications for liver disease. It has anti-inflammatory effects, regulates cell proliferation, modulates the fibrogenic response and protects liver tissue. Genetic variations in the GHRL gene may play a crucial role in the development of chronic hepatitis (CH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Therefore, we examined the association of GHRL gene polymorphisms (rs26312 and rs27647), and its serum level to virologic responses to combined sofosbuvir and Simeprevir therapy for a course of 12 successive weeks in Egyptian chronic hepatitis C (CHC) patients...
January 25, 2018: Gene
Said A Al-Busafi, Halima Al-Shuaili, Heba Omar, Haifa Al-Zuhaibi, L Jeyaseelan, Khalid Al-Naamani
Objectives: Chronic hepatitis C (CHC) is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. However, there is a lack of data regarding the epidemiology of CHC in Oman. This study aimed to describe the clinicopathological characteristics and outcomes of CHC-infected patients at a tertiary care hospital in Oman. Methods: This retrospective descriptive hospital-based study included all CHC-infected patients who presented to the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between January 2010 and December 2015...
November 2017: Sultan Qaboos University Medical Journal
Song Feng, Lu Gao, Xinchun Han, Taishan Hu, Yimin Hu, Haixia Liu, Andrew William Thomas, Zhipeng Yan, Song Yang, John A T Young, Hongying Yun, Wei Zhu, Hong C Shen
The chronic infection of hepatitis B virus (HBV) inflicts 250 million people worldwide representing a major public health threat. A significant sub-population of chronically infected HBV patients eventually develop cirrhosis and hepatocellular carcinoma (HCC) which aggravate the issues caused by hepatitis alone. Unfortunately, none of the current standard therapies for chronic Hepatitis B (CHB) result in a satisfactory clinical cure rate. Driven by a highly unmet medical need for novel and more effective treatments of HBV infection, multiple pharmaceutical companies and research institutions have been engaged in drug discovery and development to improve the CHB functional cure rate, which is defined by sustainable viral suppression and HBsAg clearance after a finite treatment...
January 25, 2018: ACS Infectious Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"